Marketing material commissioned by Cantargia.
Aktuellt
SENASTE
The past few months have been very positive for Cantargia. Most encouraging, in our view, is the recently published and promising interim results for its ongoing phase IIa CANFOUR trial. In its Q3 report, Cantargia repeated the message that it is planning its next steps forward. We argue that these next steps –along with the full results from CANFOUR and the readouts from Novartis's canakinumab trials – represent the next key triggers for the share.
LÄS MER
